Prospective Evaluation of the Prediction Score for a Mild Course of Crohn’s Disease (PreMiCC) in Newly Diagnosed Patients With Crohn’s Disease: The PROGNOS Study

Wolfgang Kruis,Bernd Bokemeyer,Petra Jessen,Mark Hoesl,Michael Mroß,Julia Morgenstern,Birgitta Reimers,Nike Müller-Grage,Ludger Leifeld

DOI: https://doi.org/10.1093/ibd/izae086

2024-04-22

Inflammatory Bowel Diseases

Abstract:Abstract Background and Aims The course of Crohn’s disease (CD) is highly variable. The Prospektive Evaluation eines Score zur Vorhersage eines milden Verlaufsbei neu diagnostizierten Morbus Crohn-Patienten in gastroenterologischen Fachpraxen (PROGNOS) study aimed to determine the frequency of a mild disease course and validate a proposed prediction score. Methods The PROGNOS study is a prospective study of CD patients who were newly diagnosed and, except for 1 course of 5-aminosalicylic acid or steroids for ≤10 days, therapy-naïve. Among other predefined inclusion criteria, the initial diagnosis had to be made ≤6 weeks before enrollment. All inception cohort patients were diagnosed and screened consecutively in participating gastroenterology practices in Germany specialized in inflammatory bowel disease. All screened CD patients were scored and, if possible, included in the study for up to 5 years (NCT02193048). Results A total of 201 CD patients were included in the study (43.3% male; mean age 33 years, mean follow-up 38 months). Altogether, 29.5% of the patients had a mild course at 36 months. Among those with a score ≤2, therapy escalation at 36 months was necessary for only 24.2%, whereas in the group with a score >2, therapy escalation was necessary for 70.2% of patients. In the Kaplan-Meier curve showing time to therapy escalation in the 2 groups, there was a pronounced and statistically significant divergence of the curves starting at 3 months and extending to 48 months (P < .001). Conclusions In this prospective study, about 30% of incident CD patients had a mild disease course. Our suggested PreMiCC (prediction score for a mild course of Crohn’s disease) successfully predicted this.

gastroenterology & hepatology

What problem does this paper attempt to address?

### Problems the Paper Attempts to Solve

This paper aims to address the high variability in the course of Crohn's disease (CD). Specifically, the research objectives include:

1. **Determine the frequency of mild disease course**: By prospectively evaluating newly diagnosed Crohn's disease patients, determine how many patients will experience a mild disease course.
2. **Validate the predictive score**: Validate the effectiveness of the previously proposed predictive score (PreMiCC) for predicting a mild disease course in newly diagnosed Crohn's disease patients.

### Background and Purpose

The course of Crohn's disease is highly variable, requiring selective treatment strategies. Some patients may develop complications, while others may experience a milder disease course. Therefore, early identification of the type of disease course is crucial for developing appropriate treatment plans. This study aims to validate the effectiveness of the PreMiCC score in predicting a mild disease course through a prospective evaluation of newly diagnosed Crohn's disease patients.

### Methods

- **Study Design**: This is a multicenter, non-interventional prospective study that included newly diagnosed Crohn's disease patients from 18 gastroenterology clinics in Germany specializing in inflammatory bowel disease (IBD).
- **Inclusion Criteria**: Patients must be included in the study within 6 weeks of diagnosis and must not have received prior treatment or only short-term oral corticosteroids or mesalazine treatment.
- **Assessment Method**: Patients were classified using the PreMiCC score, which ranges from 0 to 6 points and includes parameters such as age, C-reactive protein (CRP), endoscopic findings, perianal disease, and complications.

### Results

- **Frequency of Mild Disease Course**: Among 201 patients, 29.5% experienced a mild disease course within 36 months.
- **Effectiveness of the Predictive Score**: The PreMiCC score successfully predicted a mild disease course. Among patients with a score ≤2, only 24.2% required treatment escalation within 36 months, compared to 70.2% of patients with a score >2.
- **Kaplan-Meier Curve**: Showed a significant difference in the time to treatment escalation between the two score groups, starting from 3 months and continuing to 48 months (P < 0.001).

### Conclusion

- **Frequency of Mild Disease Course**: Approximately 30% of newly diagnosed Crohn's disease patients experienced a mild disease course.
- **Effectiveness of the PreMiCC Score**: The PreMiCC score can successfully predict a mild disease course, helping to identify patients early who do not require immunosuppressive or biological treatments, thereby avoiding unnecessary treatment escalation and potential side effects.

### Help for Patient Care

- **Prediction of Mild Disease Course**: Predicting a mild disease course can help doctors choose appropriate treatment plans and avoid overtreatment.
- **Individualized Treatment**: Through the PreMiCC score, doctors can better identify patients suitable for mesalazine monotherapy and close monitoring, reducing unnecessary treatment escalation.

### Key Information

- **Known Information**: The course of Crohn's disease is highly variable, requiring selective treatment strategies.
- **New Findings**: In our prospective PROGNOS study, 29.5% of Crohn's disease patients experienced a mild disease course within 36 months, and we successfully predicted this using the PreMiCC score.
- **Clinical Application**: Among newly diagnosed Crohn's disease patients, approximately 30% experienced a mild disease course without the need for immunosuppressive or biological treatments. Predicting a mild disease course will help in selecting appropriate treatment plans.